Abstract
INTRODUCTION:Vitamin D acts in many tissues and different physiological processes. The objective was to determine vitamin D levels in patients with epilepsy treated with anticonvulsants.
MATERIALS AND METHOD:Observational, descriptive, cross-section study in consecutive patients with epilepsy who attended the Neurology outpatient service of a university hospital in Neiva, Colombia, between March and October 31, 2018. We obtained serum levels of vitamin D, parathormone, albumin and calcium.
RESULTS:There were 90 patients with a median age of 36.5 (range 18-81 years), 46 (51.1%) had low levels of vitamin D (38.8% in the range of insufficiency and 12.2% with deficiency). Females had more insufficient and deficient levels of vitamin D; not exercising was associated with insufficient levels of vitamin D, daily exposure to the sun under 15 minutes and not walking, with deficient levels of vitamin D. Vitamin D deficiency was associated with an increase in parathyroid hormone levels, median 103.9 pg / ml (range 30.7 - 182.9 pg / ml, P <0.01). No difference was found between vitamin D levels and the use of monotherapy, polytherapy, or the use of enzyme-inducing drugs.
CONCLUSIONS:In epileptic patients with anticonvulsants it is common to find insufficient / deficient levels of vitamin D although we found no association with the use of monotherapy, polytherapy or hepatic enzyme inducers.
References
Bouillon R, Marcocci C, Carmeliet G, Bikle D, White JH, Dawson-Hughes B, et al. Skeletal and extraskeletal actions of vitamin d: current evidence and outstanding questions. Endocr Rev. 2018;40(4):1109-51. doi:10.1210/er.2018-00126.
Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JPA. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ. 2014;348:g2035. doi:10.1136/bmj.g2035.
Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006;96:252-261. doi: 10.2105/AJPH.2004.045260.
Vaughan-Shaw PG, O'Sullivan F, Farrington SM, Theodoratou E, Campbell H, Dunlop MG, et al. The impact of vitamin D pathway genetic variation and circulating 25-hydroxyvitamin D on cancer outcome: systematic review and meta-analysis. Br J Cancer. 2017;116(8):1092-110. doi: 10.1038/bjc.2017.44.
Vacek JL, Vanga SR, Good M, Lai SM, Lakkireddy D, Howard PA. Vitamin D deficiency and supplementation and relation to cardiovascular health. Am J Cardiol. 2012;109(3):359-63. doi: 10.1016/j.amjcard.2011.09.020.
Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33-44. doi: 10.1056/NEJMoa1809944.
Scragg R, Stewart AW, Waayer D, Lawes CMM, Toop L, Sluyter J, et al. Effect of monthly high-dose vitamin d supplementation on cardiovascular disease in the vitamin D assessment study : a randomized clinical trial. JAMA Cardiol. 2017;2(6):608-16. doi: 10.1001/jamacardio.2017.0175.
Hollo A, Clemens Z, Lakatos P. Epilepsy and vitamin D. Int J Neurosci. 2014;124(6):387-93. doi: 10.3109/00207454.2013.847836.
Navarro Mendoza E-P, Tejada Marín J-W, Carrillo DC, Guzmán GE, Arango LG. Prevalencia de la insuficiencia de vitamina D en pacientes con osteoporosis. Rev Colomb Reumatol. 2016;23(1):17-23. doi: 10.1016/j.rcreu.2015.12.006.
Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health problem?. J Steroid Biochem Mol Biol. 2014;144 Pt A:138-45. doi: 10.1016/j.jsbmb.2013.11.003.
Mithal A, Wahl DA, Bonjour J-P, Burckhardt P, Dawson-Hughes B, Eisman JA, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009;20(11):1807-20. doi: 10.1007/s00198-009-0954-6.
Hansen KE, Johnson MG. An update on vitamin D for clinicians. Curr Opin Endocrinol Diabetes Obes. 2016;23(6):440-4. doi: 10.1097/MED.0000000000000288.
Forrest KY, Stuhldreher WL. Prevalence and correlates of vitamin D deficiency in US adults. Nutr Res. 2011;31(1):48-54. doi: 10.1016/j.nutres.2010.12.001.
Quintana Duque M, Toro C, Restrepo J. Vitamina D en America Latina. Rev Metab Óseo Miner. 2007;5:403-10.
Tovar AP, Vásquez N, Celemin C. Niveles de vitamina D en pacientes con osteoporosis en la ciudad de Neiva, Huila, Colombia. Revista Colombiana de Endocrinología, Diabetes & Metabolismo 2017;2(3):44-50.
Vásquez-Awad D, Cano-Gutiérrez CA, Gómez-Ortiz A, González MA, Guzmán-Moreno R, Martínez-Reyes JI, et al. Vitamina D. Consenso colombiano de expertos. Medicina (Bogotá). 2017;39(2):140-57.
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-30. doi: 10.1210/jc.2011-0385.
Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia. 2004;45(11):1330-7. doi: 10.1111/j.0013-9580.2004.18804.x.
Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia. 2006;47(3):510-5. doi: 10.1111/j.1528-1167.2006.00460.x.
Jette N, Lix LM, Metge CJ, Prior HJ, McChesney J, Leslie WD. Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. Arch Neurol. 2011;68(1):107-12. doi: 10.1001/archneurol.2010.341.
Souverein PC, Webb DJ, Petri H, Weil J, Van Staa TP, Egberts T. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia. 2005;46(2):304-10. doi: 10.1111/j.0013-9580.2005.23804.x.
Shen C, Chen F, Zhang Y, Guo Y, Ding M. Association between use of antiepileptic drugs and fracture risk: a systematic review and meta-analysis. Bone. 2014;64:246-53. doi: 10.1016/j.bone.2014.04.018.
Nagarjunakonda S, Amalakanti S, Uppala V, Rajanala L, Athina S. Vitamin D in epilepsy: vitamin D levels in epilepsy patients, patients on antiepileptic drug polytherapy and drug-resistant epilepsy sufferers. Eur J Clin Nutr. 2016;70(1):140-2. doi: 10.1038/ejcn.2015.127.
Ramírez-Jiménez JJ, Alfaro-Velásquez JM. Efecto de los medicamentos antiepilépticos en el metabolismo de la vitamina D y el impacto negativo relacionado al déficit. Med Lab. 2015;21(3-4):131-48.
Menon B, Harinarayan CV. The effect of anti epileptic drug therapy on serum 25-hydroxyvitamin D and parameters of calcium and bone metabolism-- a longitudinal study. Seizure. 2010;19(3):153-8. doi: 10.1016/j.seizure.2010.01.006.
Fraser LA, Burneo JG, Fraser JA. Enzyme-inducing antiepileptic drugs and fractures in people with epilepsy: A systematic review Epilepsy Res. 2015;116:59-66. doi: 10.1016/j.eplepsyres.2015.07.003.
Nicholas JM, Ridsdale L, Richardson MP, Grieve AP, Gulliford MC. Fracture risk with use of liver enzyme inducing antiepilep-tic drugs in people with active epilepsy: cohort study using the general practice research database. Seizure. 2013;22(1):37-42. doi: 10.1016/j.seizure.2012.10.002.
Pack AM, Morrell MJ, Randall A, McMahon DJ, Shane E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology. 2008;70(18):1586-93. doi: 10.1212/01.wnl.0000310981.44676.de.
Phabphal K, Geater A, Limapichat K, Sathirapanya P, Setthawatcharawanich S, Leelawattana R. Effect of switching hepatic enzyme-inducer antiepileptic drug to levetiracetam on bone mineral density, 25 hydroxyvitamin D, and parathyroid hormone in young adult patients with epilepsy. Epilepsia. 2013;54(6):e94-8. doi: 10.1111/epi.12162.
Teagarden DL, Meador KJ, Loring DW. Low vitamin D levels are common in patients with epilepsy. Epilepsy Res. 2014;108(8):1352-6. doi: 10.1016/j.eplepsyres.2014.06.008.
Gutiérrez-Alvarez AM, Gavilanes AV, Velosa DM. Enfermedad ósea asociada al uso de antiepilépticos: la buscan los neurólogos? Acta Neurol Colomb. 2008;24(4).
Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, et al. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial. Epilepsia. 2013;54(11):1997-2004. doi: 10.1111/epi.12351.
Fernandez H, Mohammed HT, Patel T. Vitamin D supplementation for bone health in adults with epilepsy: A systematic review. Epilepsia. 2018;59(4):885-96. doi: 10.1111/epi.14015.
Miziak B, Blaszczyk B, Chroscinska-Krawczyk M, Danilkiewicz G, Jagiello-Wojtowicz E, Czuczwar SJ. The problem of osteoporosis in epileptic patients taking antiepileptic drugs. Expert Opin Drug Saf.. 2014;13(7):935-46. doi: 10.1517/14740338.2014.919255.
Fisher RS, Cross JH, D'Souza C, French JA, Haut SR, Higurashi N, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017;58(4):531-42. doi: 10.1111/epi.13671.
Suljic EM, Mehicevic A, Mahmutbegovic N. Effect of long-term carbamazepine therapy on bone health. Med Arch. 2018;72(4):262-6. doi: 10.5455/medarh.2018.72.262-266.
Jovel CE, Pardo C, Moreno C, Vergara J, Hedmont D, Mejía FS. Demographic and social profile of epilepsy in a vulnerable low-income population in Bogotá, Colombia. 2016;31(8):528-34. doi: 10.1016/j.nrl.2014.10.016. Epub 2014 Dec 15.
Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta. 2011;1814(1):186-99. doi: 10.1016/j.bbapap.2010.06.022.
Fitzpatrick LA. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav. 2004;5 Suppl 2:S3-15. doi: 10.1016/j.yebeh.2003.11.026.
Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia. 2002;43(12):1488-92. doi: 10.1046/j.1528-1157.2002.13002.x.
Verrotti A, Coppola G, Parisi P, Mohn A, Chiarelli F. Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg. 2010;112(1):1-10. doi: 10.1016/j.clineuro.2009.10.011.
Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011;364(3):248-54. doi: 10.1056/NEJMc1101911.
Misra A, Aggarwal A, Singh O, Sharma S. Effect of carbamazepine therapy on vitamin D and parathormone in epileptic children. Pediatr Neurol. 2010;43(5):320-4. doi: 10.1016/j.pediatrneurol.2010.05.013.
Greene-Finestone LS, Berger C, de Groh M, Hanley DA, Hidiroglou N, Sarafin K, et al. 25-Hydroxyvitamin D in Canadian adults: biological, environmental, and behavioral correlates. Osteoporos Int. 2011;22(5):1389-99. doi: 10.1007/s00198-010-1362-7.
Suarez-Martinez EB, Perez CM, Cruz SK, Khorsandi S, Chardon C, Ferder L. Importance of vitamin D and vitamin D levels status in Puerto Ricans. J Health Care Poor Underserved. 2013;24(4 Suppl):38-47. doi: 10.1353/hpu.2014.0000.
Ginde AA, Liu MC, Camargo CA, Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med. 2009;169(6):626-32. doi: 10.1001/archinternmed.2008.604.
Tombini M, Palermo A, Assenza G, Pellegrino G, Benvenga A, Campana C, et al. Calcium metabolism serum markers in adult patients with epilepsy and the effect of vitamin D supplementation on seizure control. Seizure. 2018;58:75-81. doi: 10.1016/j.seizure.2018.04.008.
Alshahrani F, Aljohani N. Vitamin D: deficiency, sufficiency and toxicity. Nutrients. 2013;5(9):3605-16. doi: 10.3390/nu5093605.
Cebeci AN, Ekici B. Epilepsy treatment by sacrificing vitamin D. Expert Rev Neurother. 2014;14(5):481-91. doi: 10.1586/14737175.2014.905742.
Harijan P, Khan A, Hussain N. Vitamin D deficiency in children with epilepsy: Do we need to detect and treat it?. J Pediatr Neurosci.2013;8(1):5-10. doi: 10.4103/1817-1745.111413
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.